Analyst Price Targets — TGTX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 15, 2026 12:51 am | — | Goldman Sachs | $39.00 | $29.54 | TheFly | TG Therapeutics price target raised to $39 from $37 at Goldman Sachs |
| October 6, 2025 10:11 am | Emily Bodnar | H.C. Wainwright | $60.00 | $36.71 | TheFly | TG Therapeutics assumed with a Buy at H.C. Wainwright |
| November 5, 2024 11:41 am | Edward White | H.C. Wainwright | $27.50 | $12.93 | StreetInsider | TG Therapeutics (TGTX) PT Raised to $55 at H.C. Wainwright |
| August 6, 2024 6:02 pm | Corinne Jenkins | Goldman Sachs | $20.00 | $20.58 | TheFly | TG Therapeutics price target raised to $20 from $18 at Goldman Sachs |
| May 3, 2024 6:46 am | Edward White | H.C. Wainwright | $24.50 | $8.21 | StreetInsider | TG Therapeutics (TGTX) PT Raised to $49 at H.C. Wainwright |
| February 7, 2023 7:34 am | — | Cantor Fitzgerald | $24.00 | $18.48 | Benzinga | Cantor Fitzgerald Maintains Overweight on TG Therapeutics, Raises Price Target to $24 |
| December 30, 2022 9:21 am | — | Evercore ISI | $16.00 | $11.83 | Benzinga | Evercore ISI Group Maintains Outperform on TG Therapeutics, Raises Price Target to $16 |
| December 29, 2022 6:10 am | Edward White | H.C. Wainwright | $12.00 | $4.23 | TheFly | TG Therapeutics price target raised to $24 from $19 at H.C. Wainwright |
| April 19, 2022 10:24 am | — | Goldman Sachs | $5.00 | $7.26 | Benzinga | Goldman Sachs Maintains Sell on TG Therapeutics, Lowers Price Target to $5 |
| April 18, 2022 12:00 am | Mayank Mamtani | Telsey Advisory | $11.50 | $3.46 | TipRanks Contributor | Has TG Therapeutics Stock Hit Bottom? Looking for the Silver Lining |
Latest News for TGTX
TG Therapeutics remains a "Strong Buy," driven by robust BRIUMVI revenue growth and ambitious expansion initiatives. The company reported $594 million in 2025 U.S. BRIUMVI sales, a 90% YoY increase, and guides for $825–$850 million in 2026. Key catalysts include the phase 3 ENHANCE study (consolidated dosing) and a self-administered subcutaneous BRIUMVI, both targeting significant market segments.
TG Therapeutics misses Q4 earnings estimates, but total revenues surge 78% y/y on strong Briumvi sales. The company reaffirms its 2026 revenue outlook.
TG Therapeutics, Inc. (TGTX) Q4 2025 Earnings Call Transcript
TG Therapeutics (TGTX) came out with quarterly earnings of $0.14 per share, missing the Zacks Consensus Estimate of $0.35 per share. This compares to earnings of $0.15 per share a year ago.
Fourth quarter and full year 2025 total revenue of $192.6 million and $616.3 million, including BRIUMVI U.S. net revenue of $182.7 million and $594.1 million, respectively
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TGTX.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.